Radiation Injury - Pipeline Review, H1 2015

Published: Jun, 2015 | Pages: 50 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Radiation Injury - Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Radiation Injury - Pipeline Review, H1 2015', provides an overview of the Radiation Injury's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Radiation Injury, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Radiation Injury and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Radiation Injury
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Radiation Injury and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Radiation Injury products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Radiation Injury pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Radiation Injury
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Radiation Injury pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Radiation Injury Overview 6
Therapeutics Development 7
Pipeline Products for Radiation Injury - Overview 7
Pipeline Products for Radiation Injury - Comparative Analysis 8
Radiation Injury - Therapeutics under Development by Companies 9
Radiation Injury - Therapeutics under Investigation by Universities/Institutes 10
Radiation Injury - Pipeline Products Glance 11
Early Stage Products 11
Radiation Injury - Products under Development by Companies 12
Radiation Injury - Products under Investigation by Universities/Institutes 13
Radiation Injury - Companies Involved in Therapeutics Development 14
Atox Bio Inc. 14
Cleveland BioLabs, Inc. 15
Cumberland Pharmaceuticals, Inc. 16
Humanetics Corporation 17
PharmaIN Corporation 18
RestorGenex Corporation 19
Radiation Injury - Therapeutics Assessment 20
Assessment by Monotherapy Products 20
Assessment by Target 21
Assessment by Mechanism of Action 23
Assessment by Route of Administration 25
Assessment by Molecule Type 27
Drug Profiles 29
AB-103 - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
BIO-300 - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
C-2E5 - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
CBLB-613 - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
HSJ-0017 - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
Recombinant Protein to Activate FGF-4 for Radiation Injury - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
Recombinant Protein to Activate FGF-7 for Radiation Injury - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
RES-529 - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
Small Molecule to Inhibit GSK-3 for Acute and Late Radiation Injury - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
Small Molecules to Activate Vitamin D Receptor for Radiation Injury - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
Radiation Injury - Recent Pipeline Updates 43
Radiation Injury - Dormant Projects 47
Radiation Injury - Dormant Projects 47
Radiation Injury - Discontinued Products 48
Appendix 49
Methodology 49
Coverage 49
Secondary Research 49
Primary Research 49
Expert Panel Validation 49
Contact Us 49
Disclaimer 50

List of Tables

Number of Products under Development for Radiation Injury, H1 2015 7
Number of Products under Development for Radiation Injury - Comparative Analysis, H1 2015 8
Number of Products under Development by Companies, H1 2015 9
Number of Products under Investigation by Universities/Institutes, H1 2015 10
Comparative Analysis by Early Stage Development, H1 2015 11
Products under Development by Companies, H1 2015 12
Products under Investigation by Universities/Institutes, H1 2015 13
Radiation Injury - Pipeline by Atox Bio Inc., H1 2015 14
Radiation Injury - Pipeline by Cleveland BioLabs, Inc., H1 2015 15
Radiation Injury - Pipeline by Cumberland Pharmaceuticals, Inc., H1 2015 16
Radiation Injury - Pipeline by Humanetics Corporation, H1 2015 17
Radiation Injury - Pipeline by PharmaIN Corporation, H1 2015 18
Radiation Injury - Pipeline by RestorGenex Corporation, H1 2015 19
Assessment by Monotherapy Products, H1 2015 20
Number of Products by Stage and Target, H1 2015 22
Number of Products by Stage and Mechanism of Action, H1 2015 24
Number of Products by Stage and Route of Administration, H1 2015 26
Number of Products by Stage and Molecule Type, H1 2015 28
Radiation Injury Therapeutics - Recent Pipeline Updates, H1 2015 43
Radiation Injury - Dormant Projects, H1 2015 47
Radiation Injury - Discontinued Products, H1 2015 48